M V Bielsa-Fernández, J L Tamayo-de la Cuesta, J Lizárraga-López, J M Remes-Troche, R Carmona-Sánchez, J M Aldana-Ledesma, J M Avendaño-Reyes, M A Ballesteros-Amozorrutia, M De Ariño, L de Giau-Triulzi, R Flores-Rendón, H Huerta-Guerrero, J A González-González, A Hernández-Guerrero, E Murcio-Pérez, J O Jáquez-Quintana, A Meixueiro-Daza, J R Nogueira-de Rojas, H Rodríguez-Hernández, R Santoyo-Valenzuela, S C Solorzano-Olmos, L F Uscanga-Domínguez, F Zamarripa-Dorsey
More than 30 million persons worldwide take nonsteroidal anti-inflammatory drugs (NSAIDs) on a daily basis, and annual consumption is increasing. In addition to their analgesic and anti-inflammatory properties, NSAIDs also produce well-known gastrointestinal adverse events. There is no consensus in Mexico on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy, and so the Asociación Mexicana de Gastroenterología brought together a group of experts to establish useful recommendations for the medical community...
2020: Revista de Gastroenterología de México